TriSalus Life Sciences, Inc. (TLSI)
Nasdaq · Surgical & Medical Instruments & Apparatus · Manufacturing · CIK 1826667 · fiscal year ends in Dec
Closing price $3.70 on 30 Oct 2026; 52-week range $2.52 to $7.50.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $45.1M
- Revenue growth
- 25.2%
- Net income, last twelve months
- -$28.2M
- Earnings per share
- -$1.30
- Gross margin
- 85.8%
- Operating margin
- -67.7%
- Net margin
- -62.6%
- Free cash flow
- -$23.3M
- Return on equity
- -430.7%
- Market value
- $227.4M
- Cash
- $46.3M
- Debt
- $33.1M
- Debt to equity
- 5.05
- Shares outstanding
- 61.5M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $45.2M | -$26.9M | -$39.2M | -$1.84 | -$18.9M | 10-K filed 5 Mar 2026 |
| FY2024 | 31 Dec 2024 | $29.4M | -$36.2M | -$30.0M | -$1.31 | -$41.2M | 10-K filed 15 Apr 2025 |
| FY2023 | 31 Dec 2023 | $18.5M | -$54.5M | -$59.4M | -$6.73 | -$51.2M | 10-K filed 11 Apr 2024 |
| FY2022 | 31 Dec 2022 | $12.4M | -$36.4M | -$47.2M | -$161.55 | -$33.0M | 10-K filed 11 Apr 2024 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $11.4M | -$9.2M | -$0.16 |
| Q1 FY2026 | 31 Mar 2026 | $8.9M | $1.5M | $0.03 |
| Q4 FY2025 | 31 Dec 2025 | $13.2M | -$9.8M | -$0.21 |
| Q3 FY2025 | 30 Sep 2025 | $11.6M | -$10.8M | -$0.96 |
| Q2 FY2025 | 30 Jun 2025 | $11.2M | -$8.3M | -$0.27 |
| Q1 FY2025 | 31 Mar 2025 | $9.2M | -$10.4M | -$0.39 |
| Q4 FY2024 | 31 Dec 2024 | $8.3M | -$10.1M | -$0.40 |
| Q3 FY2024 | 30 Sep 2024 | $7.3M | -$2.4M | -$0.12 |
Company events
The newest 8-K filings of 87 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 22 Sep 2026 | 8-K | Other events | 8.01, 9.01 |
| 6 Aug 2026 | 8-K | Results | 2.02, 9.01 |
| 14 May 2026 | 8-K | Shareholder vote | 5.07 |
| 12 May 2026 | 8-K | Results | 2.02, 9.01 |
| 29 Apr 2026 | 8-K | Leadership change | 5.02 |
| 7 Apr 2026 | 8-K | Leadership change, Investor update | 5.02, 7.01, 9.01 |
| 5 Mar 2026 | 8-K | Results | 2.02, 9.01 |
| 20 Feb 2026 | 8-K | Material agreement, Other events | 1.01, 8.01, 9.01 |
| 9 Feb 2026 | 8-K | Leadership change, Investor update | 5.02, 7.01, 9.01 |
| 12 Jan 2026 | 8-K | Results | 2.02, 9.01 |
| 13 Nov 2025 | 8-K | Results | 2.02, 9.01 |
| 1 Oct 2025 | 8-K | Leadership change | 5.02 |
Every filing
The newest filings with the SEC of 259 held.
| Filed | Form | Period |
|---|---|---|
| 22 Sep 2026 | 8-K | 22 Sep 2026 |
| 6 Aug 2026 | 10-Q | 30 Jun 2026 |
| 6 Aug 2026 | 8-K | 6 Aug 2026 |
| 14 May 2026 | 8-K | 14 May 2026 |
| 12 May 2026 | 10-Q | 31 Mar 2026 |
| 12 May 2026 | 8-K | 12 May 2026 |
| 29 Apr 2026 | 8-K | 24 Apr 2026 |
| 7 Apr 2026 | 8-K | 1 Apr 2026 |
| 31 Mar 2026 | ARS | 31 Dec 2025 |
| 31 Mar 2026 | DEFA14A | – |
| 31 Mar 2026 | DEF 14A | 31 Dec 2025 |
| 10 Mar 2026 | S-8 | – |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 5 Oct 2026 | Cox Bryan F., Chief of Research | Sale outside a trading plan | 296 | $4.39 | $1.3K | 162,805 | 7 Oct 2026 |
| 5 Oct 2026 | Marshak Richard, Chief Commercial Officer | Sale outside a trading plan | 325 | $4.39 | $1.4K | 127,994 | 7 Oct 2026 |
| 5 Oct 2026 | Stevens Jennifer, Chief Regulatory Officer | Sale outside a trading plan | 316 | $4.39 | $1.4K | 123,794 | 7 Oct 2026 |
| 15 May 2026 | Marshak Richard, Chief Commercial Officer | Sale outside a trading plan | 543 | $2.67 | $1.4K | 125,101 | 19 May 2026 |
| 15 May 2026 | Wahlstrom Mats, Director | Purchase | 60,000 | $2.53 | $151.8K | 147,555 | 18 May 2026 |
| 15 May 2026 | Stansky Michael P, Director | Purchase | 410,000 | $2.50 | $1.0M | 1,240,722 | 18 May 2026 |
| 15 May 2026 | Stansky Michael P, Director | Purchase | 200,000 | $2.50 | $500.0K | 399,698 | 18 May 2026 |
| 15 May 2026 | Szela Mary T, CEO and President | Purchase | 39,682 | $2.59 | $102.8K | 1,065,215 | 18 May 2026 |
| 15 May 2026 | Patience David, Chief Financial Officer | Purchase | 7,100 | $2.43 | $17.3K | 275,757 | 18 May 2026 |
| 15 May 2026 | Gordon Gary B., Director | Purchase | 10,000 | $2.46 | $24.6K | 72,510 | 18 May 2026 |
| 14 May 2026 | Wahlstrom Mats, Director | Took pay in stock | 34,226 | – | – | – | 15 May 2026 |
| 14 May 2026 | Gordon Gary B., Director | Took pay in stock | 24,553 | – | – | – | 15 May 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 7 Jul 2026 | First Light Asset Management, LLC | 13G amended | 10.74% | 6.6M |
| 20 May 2026 | James J. Pallotta | 13G amended | 5.2% | 3.2M |
| 15 May 2026 | First Light Asset Management, LLC | 13G | 8.75% | 5.4M |
| 12 May 2026 | Utmost Group PLC | 13G | 5.71% | 3.5M |
| 14 Nov 2025 | Nantahala Capital Management, LLC | 13G amended | 4.09% | 2.0M |
| 3 Nov 2025 | Utmost Group PLC | 13G | 6.79% | 3.4M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 3.4M | +2.94% | 20.11 |
| 30 Sep 2026 | 3.3M | +0.04% | 4.41 |
| 15 Sep 2026 | 3.3M | -9.41% | 28.81 |
| 31 Aug 2026 | 3.7M | -2.59% | 35.88 |
| 14 Aug 2026 | 3.8M | +0.47% | 14 |
| 31 Jul 2026 | 3.8M | +5.85% | 22.15 |
| 15 Jul 2026 | 3.6M | +15.72% | 12.88 |
| 30 Jun 2026 | 3.1M | +40.72% | 4.54 |
Funds that hold it
From each fund's latest Form 13F.
93 funds held it at 30 Jun 2026: 55 added and 9 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| First Light Asset Management, LLC | 6,552,491 | $29.8M | +1,485,664 |
| BlackRock, Inc. | 2,659,218 | $12.1M | +1,159,671 |
| Nantahala Capital Management, LLC | 2,000,000 | $9.1M | – |
| Vanguard Capital Management LLC | 1,729,385 | $7.9M | +382,349 |
| Cerity Partners LLC | 1,603,538 | $7.3M | +816,266 |
| Geode Capital Management, LLC | 1,190,067 | $5.4M | +412,973 |
| Gilder Gagnon Howe & Co. LLC | 850,081 | $3.9M | -38,434 |
| State Street Corp. | 610,963 | $2.8M | +282,943 |
| White Pine Capital LLC | 547,577 | $2.5M | +183,922 |
| Thompson Siegel & Walmsley LLC | 536,534 | $2.4M | -47,040 |
Peers
Companies in the same industry.
- Stryker Corp. (SYK): revenue $26.3B, market value $110.9B
- 3M Co. (MMM): revenue $25.2B, market value $90.1B
- Boston Scientific Corp. (BSX): revenue $21.0B, market value $60.8B
- Becton Dickinson & Co. (BDX): revenue $20.8B, market value $53.9B
- Medline Inc. (MDLN): revenue –, market value $42.2B
- Resmed Inc. (RMD): revenue $5.7B, market value $32.3B
- Dexcom Inc. (DXCM): revenue $5.1B, market value $30.7B
- West Pharmaceutical Services Inc. (WST): revenue $3.4B, market value $28.8B
- Glaukos Corp. (GKOS): revenue $690.3M, market value $14.1B
- Solventum Corp. (SOLV): revenue $8.3B, market value $13.8B